Skip to main content
An official website of the United States government

Ado-Trastuzumab Emtansine

Placeholder slot
 (A-doh-tras-TOO-zoo-mab em-TAN-seen)

Ado-trastuzumab emtansine is a type of targeted therapy drug called an antibody–drug conjugate. It is a monoclonal antibody chemically linked to a chemotherapy drug. The antibody portion binds to HER2, a protein found in high levels on some cancer cells and causes them to grow, and delivers a drug called emtansine (or DM-1), a microtubule inhibitor, to those cells, killing them. Ado-trastuzumab emtansine may also stimulate the immune system to kill cancer cells.

US Brand Name(s)
Kadcyla
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Ado-trastuzumab emtansine is approved to treat:

Ado-trastuzumab emtansine is also being studied in the treatment of other types of cancer.

More About Ado-Trastuzumab Emtansine

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Ado-Trastuzumab Emtansine - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Targeted Therapy to Treat Cancer

Monoclonal Antibodies

Clinical Trials Accepting Patients

Find Clinical Trials for Ado-trastuzumab Emtansine - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email